Bristol-Myers Squibb (BMY) Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of OS with Opdivo Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated GBM
May 9, 2019 7:01 AM
Bristol-Myers Squibb Company (NYSE: BMY) today announced the Phase 3 CheckMate -498 trial evaluating Opdivo (nivolumab) plus radiation versus temozolomide ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
